EGFR and cancer: To gain insight into the molecular interactions of the synthesized quinazolinone derivatives, molecular docking studies were conducted against five key cancer-related targets: Topoisomerase II (PDB: 5ZAD), VEGFR2 (PDB: 3WZE), c-Met (PDB: 3U6I), EGFR (PDB: 1M17), and ERα (PDB: 3ERT).